FFAR2 and obesity due to melanocortin 4 receptor deficiency: Thus, the future studies must aim to develop highly specific and efficacious small molecules to modulate pharmacological actions of FFAR2/3 signaling, and can display a promising strategy to prevent, manage and/or treat human diseases including diabetes, obesity, Crohn’s disease, atherosclerosis, gout, asthma, cardiovascular diseases, arthritis, hypertension, and colitis.